Read-Gene S.A. (WSE:RDG)
4.980
0.00 (0.00%)
Last updated: Jun 15, 2026, 9:00 AM CET
Read-Gene Revenue
Read-Gene had revenue of 2.24M PLN in the quarter ending March 31, 2026, with 76.84% growth. This brings the company's revenue in the last twelve months to 16.54M, up 33.64% year-over-year. In the year 2025, Read-Gene had annual revenue of 15.57M with 17.67% growth.
Revenue (ttm)
16.54M
Revenue Growth
+33.64%
P/S Ratio
3.55
Revenue / Employee
827.10K
Employees
20
Market Cap
58.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.57M | 2.34M | 17.67% |
| Dec 31, 2024 | 13.23M | 3.08M | 30.38% |
| Dec 31, 2023 | 10.15M | 2.91M | 40.14% |
| Dec 31, 2022 | 7.24M | 787.35K | 12.20% |
| Dec 31, 2021 | 6.45M | 384.57K | 6.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NEUCA | 13.83B |
| Diagnostyka | 2.51B |
| Synektik Spólka Akcyjna | 794.94M |
| Voxel | 583.14M |
| BioMaxima | 60.90M |
| Sygnis | 13.02M |
| Urteste | 2.50M |
| Pharmena | 1.61M |